Comparative Pharmacology
Head-to-head clinical analysis: POTASSIUM CITRATE versus UROCIT K.
Peer-Reviewed Evidence
Head-to-head clinical analysis: POTASSIUM CITRATE versus UROCIT K.
POTASSIUM CITRATE vs UROCIT-K
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Alkalizing agent that increases urinary pH and citrate concentration; citrate chelates calcium in urine, reducing calcium oxalate and calcium phosphate supersaturation. Also provides potassium to correct hypokalemia.
Potassium citrate provides alkali (bicarbonate) upon metabolism, increasing urinary citrate and pH. Citrate chelates calcium, reducing calcium oxalate and calcium phosphate supersaturation; it also inhibits crystal aggregation and growth.
10-20 mEq (as potassium) orally three times daily with meals; maximum 100 mEq/day. Each gram of potassium citrate provides 9.25 mEq of potassium.
Initial: 10–20 mEq (2–4 tablets) orally three times daily with meals; titrate to maintain urinary citrate >320 mg/day and pH 6.5–7.2. Maximum dose: 100 mEq/day (20 tablets).
None Documented
None Documented
Clinical Note
moderatePotassium citrate + Aluminum hydroxide
"Potassium citrate can cause an increase in the absorption of Aluminum hydroxide resulting in an increased serum concentration and potentially a worsening of adverse effects."
Clinical Note
moderateAcemetacin + Potassium citrate
"The therapeutic efficacy of Potassium citrate can be decreased when used in combination with Acemetacin."
Clinical Note
moderateMethadone + Potassium citrate
"The risk or severity of adverse effects can be increased when Methadone is combined with Potassium citrate."
Clinical Note
moderateNot applicable as potassium citrate is not metabolized; urinary citrate excretion follows first-order kinetics with an effective half-life of approximately 2-3 hours for renal elimination.
Approximately 12-18 hours, reflecting steady-state maintenance with extended-release formulation; clinical significance: twice-daily dosing maintains stable serum potassium.
Renal: >99% as citrate, potassium, and bicarbonate; minimal fecal or biliary elimination.
Primarily renal; >90% of absorbed potassium is excreted unchanged in urine via renal tubular secretion and glomerular filtration.
Category C
Category C
Urinary Alkalinizer
Urinary Alkalinizer
Buprenorphine + Potassium citrate
"The risk or severity of adverse effects can be increased when Buprenorphine is combined with Potassium citrate."